Imatinib drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor that is expected to accelerate the growth of the market includes an increase in the prevalence of cancer and an increase in demand for target drug therapy. For instance, according to National Cancer Institute in 2017, the number of new leukemia cases was 62,130 and the number of mortalities was 24,500 which is driving the adoption of the imatinib drug. In addition, the Imatinib drug is used for the treatment of patients with cancer by blocking the growth of eosinophils. This drug has been attributed owing to its higher efficacy in treating Chronic Eosinophilic Leukemia, Hyper-Eosinophilic Syndrome, Gastrointestinal Stromal Tumors (GIST), and many more. However, the high cost of imatinib as compared to several substitutes such as Tarceva, Sprycel, and Tasigna may hamper the market growth.
The incidences of chronic eosinophilic leukemia are expected to increase in the future. Chronic eosinophilic leukemia (CEL) is a disorder in which eosinophil count is greater than 1500 µl in peripheral blood also known as hyper-eosinophilia. It is a rare myeloproliferative neoplasm, overproduction of eosinophils in the bone marrow. Imatinib drug is more beneficial in patients who have leukemia from a genetic mutation. Moreover, the Imatinib drug also supports in improving blood counts and symptoms very fast which makes this drug highly adopted by the targeted patient pool. Imatinib for gastrointestinal stromal tumors (GIST) is also showing a significant share as Imatinib has been the first-line therapy for GIST. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumour cells.
To Request a Sample of our Report on Imatinib Drug Market: https://www.omrglobal.com/request-sample/imatinib-drug-market-share
Market Coverage
- The market number available for – 2021-2029
- Base year- 2020
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Sun Pharmaceutical Industries Ltd., Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others.
Imatinib Drug Market Report by Segment
By Drug Formulation
- Capsules
- Tablets
By Application
- Philadelphia Positive Chronic Myeloid Leukemia
- Myeloproliferative Diseases (MPD)
- Hyper-Eosinophilic Syndrome (HES)
- Myelodysplastic Syndrome (MDS)
- Gastrointestinal Stromal Tumors (GIST)
- Others
A full Report of Imatinib Drug Market is Available @ https://www.omrglobal.com/industry-reports/imatinib-drug-market-share
Imatinib Drug Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/imatinib-drug-market-share
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
